Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05016947
Title Venetoclax Plus Inotuzumab for B-ALL
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

B-cell lymphoma

B-cell acute lymphoblastic leukemia

chronic myeloid leukemia

Therapies

Dexamethasone + Inotuzumab ozogamicin + Venetoclax

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.